Evidence map›Paper›PMID 38495131›Full record

ArticleHeliyon2024

Effect of rituximab on immune status in children with aggressive mature B-cell lymphoma/leukemia-a prospective study from CCCG-BNHL-2015.

Jiajia Dong, Zhou Xu, Xia Guo, Fanghua Ye, Chenying Fan, Ju Gao, Yijin Gao, Liangchun Yang

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07168980 (Intensive Chemotherapy Combined With Early, Adequate, and Intensive Use of Rituximab for Aggressive B-NHL in Children and Adolescents), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07168980 phase2 / phase3recruitingnot on this mapstarted 2025, after this paper: background citation

Intensive Chemotherapy Combined With Early, Adequate, and Intensive Use of Rituximab for Aggressive B-NHL in Children and Adolescents

TypeinterventionalSponsorChildren's Cancer Group, ChinaRan2025 to 2030Enrolled87ConditionsMature B-cell Non-Hodgkin LymphomaArmsCyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone, Drug: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone, Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone, Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone, Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Jiajia DongDepartment of Pediatrics, Xiangya Hospital Central South University, Changsha, China.
Zhou XuDepartment of Hematology/Oncology, School of Medicine, Shanghai Children's Medical Center, Shanghai Jiaotong University, Shanghai, China.
Xia GuoDepartment of Pediatrics, Key Laboratory of Birth Defects and Related Disease of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, China.
Fanghua YeDepartment of Pediatrics, Xiangya Hospital Central South University, Changsha, China.
Chenying FanDepartment of Pediatrics, Xiangya Hospital Central South University, Changsha, China.
Ju GaoDepartment of Pediatrics, Key Laboratory of Birth Defects and Related Disease of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, China.
Yijin GaoDepartment of Hematology/Oncology, School of Medicine, Shanghai Children's Medical Center, Shanghai Jiaotong University, Shanghai, China.
Liangchun YangDepartment of Pediatrics, Xiangya Hospital Central South University, Changsha, China.
Central South University · CNShanghai Children's Medical Center · CNSichuan University · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Limited research has been conducted on the impact of rituximab on immune function and the incidence of side effects in children undergoing combination chemotherapy for aggressive mature B-cell lymphoma/leukemia. Methods: Clinical data from 85 patients with primary pediatric aggressive mature B-cell lymphoma/leukemia, treated according to the Chinese Children's Cancer Group (CCCG)-mature B-cell non-Hodgkin lymphoma (BNHL)-2015 protocol from June 1, 2015, to December 1, 2022, were collected from three tertiary medical centers in China. Patients with pre-existing malignancies or primary immune deficiencies (PIDs) were excluded. Results: Between June 1, 2015, and December 1, 2022, 85 patients (65 [76.5%] boys and 20[23.5%] girls; mean age, 6.95 years) were enrolled, and immune data at baseline during follow-up were analyzed. At the end of chemotherapy, a higher proportion of patients in the R4 group exhibited a decrease in peripheral blood CD3 Conclusions: While the effects of rituximab in combination with intense chemotherapy for childhood aggressive mature B-cell lymphoma/leukemia on children's immune function generally recovers within six months it may still prolong the recovery from immunoglobulinemia, posing a risk of secondary infections. Further studies are required to identify children with potential primary immunodeficiencies.

Indexed as

Immune statusMature B-Cell lymphomaPediatricsRituximabSide effect

Identifiers

PMID38495131
PMCPMC10943340
OpenAlexW4392470383

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.